| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 05/22/2013 | CN102242124B Modified Keratinocyte growth factor gene and its expression in yeast |
| 05/22/2013 | CN102205118B Biological product and preparation method thereof |
| 05/22/2013 | CN102159192B Preparation method of biodegradable micro-particles containing drugs |
| 05/22/2013 | CN102139097B Pharmaceutical composition for treating cancers and preparation method thereof |
| 05/22/2013 | CN102108083B Polycyclic benzopyrone compounds and preparation method and application thereof |
| 05/22/2013 | CN102080084B Human miR-125a-5p antisense nucleotide and application thereof |
| 05/22/2013 | CN102080082B Human miR-129* antisensenucleic acid and applications thereof |
| 05/22/2013 | CN102070598B Norsesquiterpenoid peroxides and preparation method thereof |
| 05/22/2013 | CN102060757B Acylhydrazone Schiff alkali compound and preparation method and application thereof |
| 05/22/2013 | CN102036959B Polysubstituted 2-aryl-6-phenyl-imidazo[l,2-a] pyridine derivatives, and preparation and therapeutic use thereof |
| 05/22/2013 | CN102026998B Spirocyclic derivatives as histone deacetylase inhibitors |
| 05/22/2013 | CN101932580B Imidazopyridine kinase inhibitors |
| 05/22/2013 | CN101890157B Application of gastrin in inhibiting gastrointestinal tumor cells |
| 05/22/2013 | CN101862331B New use of methyl liensinine |
| 05/22/2013 | CN101849006B Improved antibody molecule |
| 05/22/2013 | CN101836991B Medicament composition containing sorafenib, cMet inhibitors and EGFR tyrosine kinase inhibitors and application thereof |
| 05/22/2013 | CN101766818B Polysaccharide gold-magnetic composite particle medicine carrier and preparation method thereof |
| 05/22/2013 | CN101605553B Treatment of gastrointestinal diseases |
| 05/22/2013 | CN101544556B Quinone compound Bostrycin, preparation method thereof and anti-tumor application thereof |
| 05/22/2013 | CN101506211B 激酶拮抗剂 Kinase antagonists |
| 05/22/2013 | CN101469019B Cellular membrane protein DERLIN-1, preparation and use thereof |
| 05/22/2013 | CN101347533B Effective component of gamene and preparation and use thereof |
| 05/22/2013 | CN101316823B 2,4,5-triphenyl imidazoline derivatives as inhibitors of interaction between p53 and MDM2 proteins for use as anticancer agents |
| 05/21/2013 | US8445694 Hydrazonopyrazole derivatives and their use as therapeutics |
| 05/21/2013 | US8445676 Pyrrolotriazine kinase inhibitors |
| 05/21/2013 | US8445660 Chimeric vaccines |
| 05/21/2013 | US8445653 Freeze-dried preparation of stabilized anthracycline compound |
| 05/21/2013 | US8445644 ErbB interface peptidomimetics and methods of use thereof |
| 05/21/2013 | US8445524 Solid forms of bendamustine hydrochloride |
| 05/21/2013 | US8445504 Tricyclic pyrazolopyrimidine derivatives |
| 05/21/2013 | US8445493 Tetrasubstituted pyridazines hedgehog pathway antagonists |
| 05/21/2013 | US8445479 Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity |
| 05/21/2013 | US8445268 Her-2/neu DNA vaccine having anti-cancer activity |
| 05/21/2013 | US8445237 RNA interference mediating small RNA molecules |
| 05/21/2013 | US8444990 Antibody-induced apoptosis |
| 05/21/2013 | US8444988 Cancer treatment method |
| 05/21/2013 | US8444979 Antibodies that inhibit TSLP activity |
| 05/21/2013 | US8444974 Use of antibodies for the vaccination against cancer |
| 05/21/2013 | US8444964 Compositions and methods for enhanced tumor cell immunity in vivo |
| 05/21/2013 | US8444957 Methods of screening for neoplastic disease states |
| 05/21/2013 | CA2583397C Therapeutic agents targeting the ncca-atp channel and methods of use thereof |
| 05/21/2013 | CA2579533C Drug delivery from embolic agents |
| 05/21/2013 | CA2571726C Prodrugs of hiv protease inhibitors |
| 05/21/2013 | CA2518541C Gonadal function improving agents |
| 05/21/2013 | CA2481499C Use of cyclopamine in the treatment of psoriasis and other skin disorders |
| 05/21/2013 | CA2478011C Bispecific antibody point mutations for enhancing rate of clearance |
| 05/21/2013 | CA2460092C A method of diagnosis and treatment and agents useful for same |
| 05/21/2013 | CA2454147C Inhibitor of dna methylation |
| 05/21/2013 | CA2436666C Use of zwitterionic polysaccharides for the specific modulation of immune processes |
| 05/21/2013 | CA2412436C Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury |
| 05/21/2013 | CA2397987C Use of at least a fatty ester for preparing a composition designed to inhibit 5 alpha reductase activity, in pharmacology, in particular dermatology, in cosmetics and as food additive |
| 05/21/2013 | CA2396688C Glycosidase inhibitors and methods of synthesizing same |
| 05/21/2013 | CA2360146C Methods for inhibiting brain tumor growth by using selected integrin antagonists |
| 05/21/2013 | CA2294865C Immunogenic lhrh compositions and methods relating thereto |
| 05/16/2013 | WO2013071217A1 Dihydropteridinones |
| 05/16/2013 | WO2013071214A1 Synergistic anti-cancer activity of sr16388 with anti-mitotic drugs |
| 05/16/2013 | WO2013071154A1 Cyclin a1-targeted t-cell immunotherapy for cancer |
| 05/16/2013 | WO2013071142A1 Biomarkers of response to proteasome inhibitors |
| 05/16/2013 | WO2013071106A1 Administration of a bis(thiohydrazide amide) compound for treating cancers |
| 05/16/2013 | WO2013071094A1 Compounds useful as inhibitors of atr kinase |
| 05/16/2013 | WO2013071090A1 Compounds useful as inhibitors of atr kinase |
| 05/16/2013 | WO2013071088A1 Compounds useful as inhibitors of atr kinase |
| 05/16/2013 | WO2013071079A1 Lin28/let-7 crystal structures, purification protocols, and molecular probes suitable for screening assays and therapeutics |
| 05/16/2013 | WO2013071068A2 Treatment of hematologic malignancies with an anti-cxcr4 antibody |
| 05/16/2013 | WO2013071058A1 Her3 antibodies and uses thereof |
| 05/16/2013 | WO2013071035A1 Macrocyclic compounds for inhibition of inhibitors of apoptosis |
| 05/16/2013 | WO2013071030A1 Provasopressin antagonists and uses thereof |
| 05/16/2013 | WO2013071027A1 Macrocyclic compounds for inhibition of inhibitors of apoptosis |
| 05/16/2013 | WO2013071016A2 Methods of inhibiting tumor growth by antagonizing il-6 receptor |
| 05/16/2013 | WO2013071001A1 Treatment of ovarian cancer with benzylidenebenzohydrazides |
| 05/16/2013 | WO2013070998A1 TREATMENT OF OVARIAN CANCER WITH 2-AMINO-4H-NAPHTHO[1,2-b]PYRAN-3-CARBONITRILES |
| 05/16/2013 | WO2013070996A1 Method of treating a proliferative disease |
| 05/16/2013 | WO2013070961A1 Modulators of atp-binding cassette transporters |
| 05/16/2013 | WO2013070911A1 Compounds and methods for treating cystic fibrosis |
| 05/16/2013 | WO2013070903A1 Method of quantifying cancer treatment |
| 05/16/2013 | WO2013070890A1 Dual inhibitor of met and vegf for treating cancer |
| 05/16/2013 | WO2013070839A1 Biomarkers for bladder cancer and methods using the same |
| 05/16/2013 | WO2013070660A1 Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction |
| 05/16/2013 | WO2013070659A1 Modulators of opioid receptors and methods of use thereof |
| 05/16/2013 | WO2013070620A1 Heterocyclic analogs of propargyl-linked inhibitors of dihydrofolate reductase |
| 05/16/2013 | WO2013070586A1 Small molecule modulators of prb inactivation |
| 05/16/2013 | WO2013070526A1 Methods for the treatment of skin neoplasms |
| 05/16/2013 | WO2013070460A1 Combination therapy for ovarian cancer |
| 05/16/2013 | WO2013070401A1 Camalexin as a treatment for prostate cancer |
| 05/16/2013 | WO2013070324A1 Edible plant-derived microvesicle compositions for diagnosis and treatment of disease |
| 05/16/2013 | WO2013069765A1 Nitrogenated heterocyclic compound |
| 05/16/2013 | WO2013069010A1 Methods for individually optimizing a cancer treatment |
| 05/16/2013 | WO2013068909A1 N-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamide for the treatment of chronic myelogenous leukemia |
| 05/16/2013 | WO2013068874A1 Antibody-drug conjugates |
| 05/16/2013 | WO2013068785A1 Indanone and indandione derivatives and heterocyclic analogs |
| 05/16/2013 | WO2013068755A1 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use |
| 05/16/2013 | WO2013068621A1 Use of a chemical compound derived from a 1,2,3,5-tetrasubstituted pyrole in the preparation of a drug for use in treating inflammatory diseases involving processes of cellular apoptosis |
| 05/16/2013 | WO2013068590A1 Lipocalin muteins as vegf antagonists for use in treating diseases caused or promoted by increased vascularization |
| 05/16/2013 | WO2013068458A1 Therapeutically active thiazolo-pyrimidine derivatives |
| 05/16/2013 | WO2013068405A1 Composition for photodynamic diagnosis and treatment of tumors |
| 05/16/2013 | WO2013067882A1 Water-soluble vitamin e derivative modified fat-soluble anti-cancer drug compound and formulation, preparation method and use thereof |
| 05/16/2013 | WO2013067881A1 Water-soluble vitamin e derivative-modified amphiphilic anticancer medicament compound and preparation, method for preparing the compound, and application thereof |
| 05/16/2013 | WO2013067767A1 Polyethylene glycol-amino acid oligopeptide-irinotecan drug conjugate and drug composition thereof |
| 05/16/2013 | WO2013067749A1 Use of (-)-epigallocatechin gallate |
| 05/16/2013 | WO2013067710A1 Nampt inhibitors |